Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Ignite Conference 2026
14 slides from Argenica Therapeutics's conference presentation, April 2026
Slide 1: Precision Neuroprotection for Severe Brain Injury
Precision Neuroprotection for Severe Brain Injury ARGENICA THERAPEUTICS Targeting patients where brain injury – and value – is greatest INVESTOR PRESENTATION IGNITE CONFERENCE – APRIL 2026 DR LIZ DALLIMORE - MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Investment Overview
INVESTMENT OVERVIEW PRECISION NEUROPROTECTION APPROACH TO SEVERE BRAIN INJURY SCIENTIFICALLY VALIDATED FIRST-IN-CLASS NEUROPROTECTIVE DRUG ARG-007 is a neuroprotective therapy targeting acute and secondary brain injury, with extensive preclinical efficacy data published on the ability of ARG-007 to
Slide 4: Key Company Metrics
KEY COMPANY METRICS $8M $20M $4M CASH @ BANK 1 MARKET CAP2 R&D Tax Rebate ARGENICA THERAPEUTICS 128.5M 37% SHARES HELD BY TOP 20 +ve DATA SHARES ON ISSUE IN PHASE 2 STROKE TRIAL 1. Cash balance as @ 31 March 2026 4 2. Calculated with closing price on @ 10th April 2026 being $0.15.5 www.argenica.com.
Slide 5: Ischaemic Stroke Opportunity
ISCHAEMIC STROKE ARGENICA THERAPEUTICS OPPORTUNITY 5 www.argenica.com.au
Slide 6: Stroke has the greatest incidence of disability and death of all neurological conditions
STROKE HAS THE GREATEST INCIDENCE OF DISABILITY AND DEATH OF ALL NEUROLOGICAL CONDITIONS1 • Stroke is the leading neurological cause of long-term disability and death, significantly greater than other leading neurological conditions. • Stroke-related costs in the United States came to nearly $56.5 b
Slide 7: This represents a huge unmet need
Number of stroke victims each year globally 1 THIS REPRESENTS A HUGE UNMET NEED 5m 4.5m 4m ~5 MILLION PEOPLE AIS Drug Treatment market valued at $10.6 Billion by 2027 1. suffering from an acute ischaemic stroke globally each year1 3.5m Current standard of care treatments for more severe stroke ARGEN
Slide 8: Phase 2 Trial Results
PHASE 2 TRIAL ARGENICA THERAPEUTICS RESULTS 8 www.argenica.com.au
Slide 9: The Phase 2 trial identified a treatment effect in more severe stroke patients
The Phase 2 trial identified a treatment effect in more severe stroke patients, paving the way for a precision-designed Phase 2b trial PHASE 2 POST HOC RESULTS • Whilst no overall effect was seen across the broader patient group due to baseline stroke severity imbalance ARGENICA THERAPEUTICS and ina
Slide 10: ARG-007 significantly reduces growth of damaged brain in moderate to severe stroke patients
ARG-007 significantly reduces growth of damaged brain in moderate to severe stroke patients ARGENICA THERAPEUTICS Figure 1: Total corrected ischaemic lesion volumes (cISC) in ml as predicted from the corresponding multivariate model across different baseline AIV values (0ml, 10ml, 20ml; 30 ml). The
Slide 11: ARG-007 significantly improved disability outcomes in patients with more severe strokes
ARG-007 significantly improved disability outcomes in patients with more severe strokes ABLE TO WALK WITHOUT ASSISTANCE ARGENICA THERAPEUTICS Figure 1: Distribution of the mRS at 90 days across treatment arms using e-ASPECTS or AIV to exclude patients with small infarct cores alongside patients with
Slide 12: Phase 2b Trial: Designed to Prove Efficacy in More Severe Strokes
PHASE 2b TRIAL: DESIGNED TO PROVE EFFICACY IN MORE SEVERE STROKES Moderate to severe stroke (ASPECTS 3-8, AI assisted interpretation) PATIENT Large Vessel Occlusion undergoing thrombectomy POPULATION With or without thrombolysis ARGENICA THERAPEUTICS mRS shift 90 days ENDPOINT mRS 0-3 in
Slide 13: Potential Catalysts for 2026
POTENTIAL CATALYSTS FOR 2026 H1 Paediatric Plan Waiver from European Medicines Agency for ARG-007 in Stroke 2026 Board Changes Completion of FDA requested in vitro assays for IND Updated clinical development strategy for Stroke & TBI European Stroke Organisation Conference, Netherlands May
Slide 14: For further information please contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 14 www.argenica.com.au